CeMines Inc. And Children's Hospital-Denver Unite In Advanced Cancer Research Involving Validation Of Childhood Leukemia Biomarkers
GOLDEN and DENVER, Colo., Jan. 27 /PRNewswire/ -- CeMines Inc., a life sciences company specializing in molecular research and development of minimally invasive clinical diagnostics and targeted therapeutics for cancer, and The Children's Hospital of Denver, the nation's leading, nonprofit pediatric healthcare network, today announced a joint clinical research project, targeted at achieving significant improvements in the diagnosis and monitoring of childhood leukemia. The joint-research project, sponsored by CeMines, is based on CeMines Molecular FingerPrinting(TM), a minimally invasive diagnostic process.
"The Children's Hospital-Denver and CeMines have undertaken this important joint initiative to adapt and improve our technology for the identification and analysis of specific mRNA structural anomalies. This is a novel application for CeMines, and we look forward to improving legacy procedures by introducing new methods of diagnosing and monitoring childhood leukemia," said Roger Attick, Chief Executive Officer of CeMines.
The research will be conducted jointly by Toomas Neuman, Ph.D., CeMines' Chief Scientific Officer (CSO), at the company's Diagnostics and Therapeutics Research Division located in La Jolla, Calif., and by Nicholas Foreman, M.D., Associate Professor of Pediatrics Tanner Seebaum and Zachary Tschetter Chair in Neuro-Oncology, and Director, Pediatric Neuro-Oncology Program, at The Children's Hospital-Denver.
"Leukemia accounts for about 25 percent of all childhood cancers and affects approximately 2,200 young Americans each year. CeMines is honored to join hands with The Children's Hospital-Denver, as we develop the world's most advanced leukemia diagnostic test available in medicine today," added Roger Attick.
"We are fortunate to work with CeMines and excited about having access to their novel technology," stated Dr. Nicholas Foreman. "CeMines Molecular FingerPrinting and, specifically, its capability to detect changes in mRNA structure in young cancer patients, has the potential to change the way we diagnose cancer," added Dr. Foreman. "We are very optimistic about the outcome of this research project with CeMines. If successful, it will have a marked impact on a physician's ability to improve survival rates for this terrible disease, and to do so based on early detection."
"Our project analyzes messenger RNA (mRNA) anomalies from pediatric patients who have been diagnosed with childhood leukemia. We will then compare the samples with those from healthy children," said Dr. Toomas Neuman, CeMines' CSO. "We are able to detect changes of blood-based cancer cells in minute quantities. Our research with Dr. Foreman is important, because it will be the very first demonstration of our CeMines Molecular FingerPrinting technology for a blood-based cancer, such as childhood leukemia," added Dr. Neuman.
CeMines, Inc(TM), a life sciences company specializing in molecular research, is developing minimally invasive clinical diagnostic tests and targeted therapeutics for cancer. CeMines' novel approach to understanding human cellular regulatory mechanisms resulted in the discovery of CeMines Molecular FingerPrinting(TM), a patent-pending bioinformatics process for identification and profiling of cancer cells. For more information, visit their website at http://www.cemines.com/.
The Children's Hospital has been ranked for more than a decade as one of the best children's hospitals nationally by U.S. News & World Report, and as the consistent choice eight years in a row by area physicians for the care of their loved ones (5280: Denver's Mile-High Magazine). Founded in 1908, The Children's Hospital is a private, not-for-profit pediatric healthcare network dedicated 100 percent to caring for kids. With 1,130 pediatric specialists and more than 2,300 full-time employees, Children's is home to a number of nationally and internationally recognized medical programs. From medical breakthroughs to late-night fevers, Children's provides complete pediatric care at its main campus and through a network that includes five community- based after-hour care sites, eight specialty-care centers, and more than 400 outreach clinics held in three states each year. For more information, visit the web site at http://www.tchden.org/.
CeMines Inc.CONTACT: Ronald C. Trahan, APR President/CEO of Ronald Trahan AssociatesInc., +1-781-762-9782, ext. 18; or Rachel Robinson, Media RelationsCoordinator of The Children's Hospital, Denver, +1-303-861-6388